Skip to content
Menu

Viridian Therapeutics, Inc. VRDN

Full chart Compare
Set alert

Price alert · VRDN

All alert types
29.70 USD -0.10 (-0.34%)

As ofNov 17, 2026, 3:07 PM EST

29.25 Day range 30.16
13.18 52-week range 34.29
YTD
-4.56%
1 year
+2.41%

Fundamental scorecard

6 of 25 checks passed on VRDN’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 1 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 128 against a 5-year median of 663.
  • Failed:Price to book below its own 5-year median Price to book 5.8 against a 5-year median of 2.6.
  • Failed:Free cash flow yield above 4% Free cash flow of -343M is -10.2% of the market value.

Growth 1 of 5

  • Failed:Revenue grew over the last year Revenue of 26.3M is -62.8% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +132.2% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS -3.86 against -3.02 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -31.13 in FY 2020, -3.32 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 1 of 5

  • Failed:Profitable over the last year Net income of -454M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -83.7%.
  • Passed:Net margin above its 5-year average Net margin of -1724.1% against a 5-year average of -35118.3%.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 1.01B against short-term liabilities of 70.1M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 1.01B against long-term liabilities of 378M.
  • Passed:Net debt under 40% of equity More cash than debt: 957M of cash against 364M of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -342M is -93.8% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -17.6 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What VRDN owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 1.03B of assets

Debt, equity and cash by year

Now: 592M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

2.21 Grey zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

2 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C-1 / 5 overall

  • DCF 1
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 2
  • P/E 1
  • P/B 2

Valuation

P/E -9.4×
P/S 37.2×
P/B 3.7×
P/FCF -9.5×
EV/EBITDA -7.3×
EV/Sales 35.0×
FCF Yield -10.5%

Profitability

Gross Margin 100.0%
Operating Margin -512.9%
Net Margin -483.6%
ROE -47.4%
ROIC -43.8%
ROA -38.1%

Growth (YoY)

Revenue 23359.9%
Operating Income -21.5%
EPS (diluted) 16.6%
Free Cash Flow -18.9%

Financial Health

Current Ratio 12.6×
Quick Ratio 12.6×
Debt / Equity 0.1×
Net Debt / EBITDA 0.5×
Interest Coverage -73.4×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31